Jennifer Brooke Valerin

Picture of Jennifer Brooke Valerin
Assistant Clinical Professor, Division of Hematology/Oncology, Medicine
School of Medicine
M.D., George Washington University School of Medicine and Health Sciences, 2009, Medicine
Ph.D., University of Texas at Houston/MD Anderson Cancer Center, 2019, Cancer Biology, Clinical and Translational Research
B.S., University of California, San Diego, 2003, Biological Sciences (Minor in Psychology)
Phone: ( 714) 456-5153
Email: jvalerin@hs.uci.edu
University of California, Irvine
200 S. Manchester Ave.
Suite 400, Room 422
Mail Code: 4061
Orange, CA 92868
Research Interests
Gastrointestinal Cancers, Hereditary Cancers, Genomic Medicine, Early Phase Clinical Trials
Academic Distinctions
Alpha Omega Alpha Medical Honor Society
Research Abstract
My clinical and research interests are to advance the care of high risk pancreatic cancer patients by providing targeting therapies based on genomic assessments. My goal is to study the response of hereditary cancer patients to novel therapeutic agents in order to develop rationally designed, hypothesis driven clinical trials with integrated strong correlative sciences. To this end, I have been extensively involved in different phases of development, implementation and analysis of clinical trials during and after fellowship. I have written phase I trials and additionally, I have been the co-principal investigator on a preoperative Phase 1B study to assess the safety and the immunological effect of Pembrolizumab (Keytruda®) in combination with paricalcitol with or without chemotherapy in patients with resectable pancreatic cancer.

I have been fortunate to develop a translational research skill-set in genomics. I have also led a program in pancreatic cancer to assess correlative analyses of a phase I clinical trial using Talazoparib, a PARP inhibitor, in solid tumors. This project was used as the foundation for my PhD work where I analyzed pancreatic BRCA-mutant patient-derived xenograft models to test for novel mechanisms of response and resistance to PARP inhibitor therapy. I was awarded both the ASCO Young Investigator Awards and the AACR Basic Science Award for my research efforts as well as the NIH Loan Repayment Award.
Publications
10. Goldstein J, Zhao L, Wang X, Ghelman Y, Overman M, Javle M, Shroff R, Varadachary G, Wolff R, McAllister F, Futreal PA, Fogelman D, Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Pancreatic Cancer Patients. Clinical Cancer Research. 2019, PMID 31871297.
9. Bannon S*, Montiel M*, Goldstein J*, Dong W, Mork M, Borras E, Hasanov M, Varadhachary G, Maitra A, Katz K, Feng L, Futreal PA, Fogelman D, Vilar E, and McAllister F, High prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. Cancer Prevention Research. 2018 Nov; 11(11): 679-686. PMID 30274973
8. Nejati, R MD, Goldstein J, MD, Halperin D, Wang H, Hejazi N, Rashid A, Katz M, Lee J, Fleming J, Rodriguez-Canales J, Blando, J, Wistuba I, Maitra A, Wolff R, Varadhachary G, Wang H, Prognostic Significance of Tumor Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. The Pancreas. 2017 Oct; 46(9):1180-1187. PMID 28902789.
7. Goldstein J, WuW, Borras E, MasandG, CuddyA, MorkM, Bannon S, Lynch P, Rodriguez-Bigas M, TaggartM, Wu JY, Scheet P, Kopetz S, You YN, Vilar E, Can Microsatellite Status of Colorectal Cancer be Reliably Assessed after Neoadjuvant Therapy? CCR. 2017, Sep; 23(17):5246-5254. PMID 28522602.
6. Goldstein J, Tang C, Hess K, Hong D, Subbiah V, Janku F, Fu S, Karp D, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary G, Wolff R, Fogelman D, Meric-Bernstam F, Piha-Paul S, Phase I Outcomes for Patients with Advanced Pancreatic Cancer: An Update on the Experience from MD Anderson Cancer Center. Oncotarget 2017, Aug 3;8(50):87163-87173. PMID 29152071.
5. Pandy R, Al-Rohil RN, Goldstein JB, Tetzlaff MT, Barnes TG, Baldwin SE, Fogelman D, Abraham SC, Piha-Paul SA, Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case. The American Journal of Dermatopathology. 2016 Nov;38(11):852-856. PMID 27043340.
4. Goldstein J, Patel A, Curry J, Subbiah V, Piha-Paul S. Photoallergic Reaction in a Patient Receiving Vandetanib for Metastatic Follicular Thyroid Carcinoma: A Case Report. BMC Dermatol 2015, Dec; 15 (1): 22. PMID 25886034
3. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman M. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014 Feb; 25(5): 1032-8. PMID 24585723.
2. Kalous K, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Finn R. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Research and Treatment 2013, Oct;141(3):397-408. PMID 24091768
1. Collicos MA, Firth SI, Bosze J, Goldstein J, Feller MB. Emergence of realistic retinal networks in culture promoted by the superior colliculus. Dev Neuroscience. 2004;26(5-6):406-16. PMID 15855770
Professional Societies
American Society of Hematology (ASH)
American Society of Clinical Oncology (ASCO)
American Association of Cancer Research (AACR)
American College of Physicians (ACP)
Medical Oncology Association of Southern California (MOASC)
Other Experience
Internal Medicine Residency
University of California, Los Angeles 2009—2012
Hematology/Oncology Fellowship
University of Texas at Houston/MD Anderson Cancer Center 2012—2015
Advanced Scholar Fellowship
University of Texas at Houston/MD Anderson Cancer Center 2015—2017
Clinical Specialist
University of Texas at Houston/MD Anderson Cancer Center 2017—2020
Research Centers
Chao Family Comprehensive Cancer Center
Last updated
10/15/2021